Pulmonary Hypertension Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035
The global pulmonary hypertension market is driven by the increasing prevalence of chronic conditions such as connective tissue diseases, congenital heart disease, and chronic obstructive pulmonary disease (COPD), which are major risk factors for pulmonary hypertension. Advances in targeted therapies, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors (PDE-5 inhibitors), and prostacyclin analogs, have improved patient outcomes by managing symptoms and slowing disease progression. The market is expanding with the approval of new biologics and combination therapies aimed at improving long-term management of pulmonary hypertension. However, challenges such as high treatment costs, delayed diagnosis, and the need for personalized care remain. The increasing awareness, early detection, and improved healthcare infrastructure in emerging markets will provide significant growth opportunities in the coming years.
Impact
The following are the drivers for the global pulmonary hypertension market:
Product/Innovation Strategy: This report provides insights into emerging therapies, such as biologic treatments and novel combination therapies, helping organizations align their R&D with the evolving market needs. It also highlights regulatory trends and patient management practices, guiding innovation to address disease progression and adherence issues.
Competitive Strategy: The report outlines the competitive landscape, focusing on market players. It offers actionable insights into market share dynamics, pricing strategies, and clinical differentiation, enabling organizations to identify opportunities for collaboration, licensing, and regional market expansion.
Key Market Players and Competition Synopsis
Key players in the global pulmonary hypertension market offering effective treatment options for pulmonary hypertension. The competitive landscape is shaped by the need for combination therapies, personalized treatment approaches, and improved patient compliance. Companies are also focusing on expanding indications, global market access, and innovative delivery systems to maintain their leadership.
Some of the prominent names established in this market are:
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
Impact
- Increasing demand for pulmonary hypertension therapies is anticipated to support the growth of the global pulmonary hypertension market during the forecast period 2025-2035.
- The global pulmonary hypertension market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
The following are the drivers for the global pulmonary hypertension market:
- Growing prevalence of pulmonary hypertension and underlying conditions: Higher incidence of connective tissue disorders, congenital heart disease, and ageing populations globally drives demand for pulmonary hypertension therapies.
- Advances in targeted therapies and combination regimens: New drugs including ERAs, PDE?5 inhibitors, soluble guanylate cyclase stimulators and prostacyclin analogues have improved clinical outcomes, encouraging broader diagnosis and treatment.
- Improved diagnostic capabilities and screening programs: Enhanced imaging, right?heart catheterization access and awareness campaigns are boosting early detection of pulmonary hypertension, translating into higher treatment uptake and market expansion.
- High cost of therapy and limited affordability: Many pulmonary hypertension treatments are high cost and require specialist administration, making access challenging in low? and middle?income regions and limiting market growth.
Product/Innovation Strategy: This report provides insights into emerging therapies, such as biologic treatments and novel combination therapies, helping organizations align their R&D with the evolving market needs. It also highlights regulatory trends and patient management practices, guiding innovation to address disease progression and adherence issues.
Competitive Strategy: The report outlines the competitive landscape, focusing on market players. It offers actionable insights into market share dynamics, pricing strategies, and clinical differentiation, enabling organizations to identify opportunities for collaboration, licensing, and regional market expansion.
Key Market Players and Competition Synopsis
Key players in the global pulmonary hypertension market offering effective treatment options for pulmonary hypertension. The competitive landscape is shaped by the need for combination therapies, personalized treatment approaches, and improved patient compliance. Companies are also focusing on expanding indications, global market access, and innovative delivery systems to maintain their leadership.
Some of the prominent names established in this market are:
- Johnson & Johnson
- Bayer AG
- Lupin
- United Therapeutics Corporation
- GSK
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
Executive Summary
Scope of Study
Research Methodology
1. GLOBAL PULMONARY HYPERTENSION MARKET: INDUSTRY OUTLOOK
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL PULMONARY HYPERTENSION MARKET (BY REGION), $MILLION, 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Pulmonary Hypertension Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Pulmonary Hypertension Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Pulmonary Hypertension Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. GLOBAL PULMONARY HYPERTENSION MARKET - COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Viatris Specialty LLC
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Johnson & Johnson
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Bayer AG
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 United Therapeutics Corporation
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Gilead Sciences, Inc.
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Lupin
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 GSK plc
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 Others
4. RESEARCH METHODOLOGY
Scope of Study
Research Methodology
1. GLOBAL PULMONARY HYPERTENSION MARKET: INDUSTRY OUTLOOK
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL PULMONARY HYPERTENSION MARKET (BY REGION), $MILLION, 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Pulmonary Hypertension Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Pulmonary Hypertension Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Pulmonary Hypertension Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. GLOBAL PULMONARY HYPERTENSION MARKET - COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Viatris Specialty LLC
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Johnson & Johnson
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Bayer AG
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 United Therapeutics Corporation
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Gilead Sciences, Inc.
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Lupin
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 GSK plc
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 Others
4. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Pulmonary Hypertension Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Pulmonary Hypertension Market, 2024 and 2035
Figure: Global Pulmonary Hypertension Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Europe Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Asia-Pacific Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Rest-of-the-World Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Pulmonary Hypertension Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Pulmonary Hypertension Market, 2024 and 2035
Figure: Global Pulmonary Hypertension Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Europe Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Asia-Pacific Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Rest-of-the-World Pulmonary Hypertension Market, $Million, 2024-2035
LIST OF TABLES
Table: Market Snapshot
Table: Market Dynamics
Table: Global Pulmonary Hypertension Market (by Region), $Million, 2024-2035
Table: Market Snapshot
Table: Market Dynamics
Table: Global Pulmonary Hypertension Market (by Region), $Million, 2024-2035
